Skip to main content
OKYO Pharma Ltd logo

OKYO Pharma Ltd — Investor Relations & Filings

Ticker · OKYO ISIN · US6793451088 US Manufacturing
Open in API
Filings indexed 274 across all filing types
Latest filing 2026-05-19 Regulatory Filings
Country US United States of America
Listing US OKYO

About OKYO Pharma Ltd

https://okyopharma.com/

OKYO Pharma Ltd. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for inflammatory eye diseases and chronic pain. The company's primary focus is on addressing significant unmet medical needs in neuropathic corneal pain (NCP) and dry eye disease (DED). Its lead product candidate, Urcosimod (OK-101), is a novel G protein-coupled receptor (GPCR) agonist that targets the chemerin receptor to produce anti-inflammatory and pain-reducing effects. OKYO is the first company to receive Investigational New Drug (IND) clearance from the FDA to clinically evaluate a drug specifically for NCP, a condition with no approved treatments. Urcosimod has also been granted Fast Track Designation by the FDA for the treatment of NCP.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings Classification · 86% confidence The document is a US SEC Form 6-K “Report of Foreign Private Issuer” filed by OKYO Pharma Ltd. It furnishes Exhibit 99.1 for the appointment to its Scientific Advisory Board. This is a regulatory filing under the Securities Exchange Act, not a financial report (10-K, IR, ER), not a management discussion, and not a direct management change of the board of directors. Under our taxonomy, Form 6-K and similar miscellaneous compliance filings are classified as Regulatory Filings (RNS).
2026-05-19 English
6-K - OKYO Pharma Ltd (0001849296) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, OKYO Pharma LTD, pursuant to SEC rules. It announces a CEO presentation at Eyecelerator and leadership participation at a conference (ARVO Annual Meeting). The document is short (2595 characters) and primarily serves as an announcement with an exhibit (99.1) that contains the actual presentation or news announcement. There is no substantive financial data or detailed report content within this filing itself. According to the 'Menu vs Meal' rule, this is an announcement of information rather than the information/report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements and filings that do not fit other categories.
2026-04-29 English
6-K - OKYO Pharma Ltd (0001849296) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, OKYO Pharma LTD, with the SEC. It announces a Scientific Advisory Board meeting related to clinical data review and strategic guidance. The document is short (2914 characters) and primarily serves as an announcement of an event rather than containing detailed financial data or comprehensive reports. It references an attached exhibit (99.1) which is a news announcement. There is no substantive financial data, earnings information, or detailed report content. According to the rules, such a document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not fit into more specific categories like Annual Report, Earnings Release, or Investor Presentation.
2026-04-07 English
6-K - OKYO Pharma Ltd (0001849296) (Filer)
Director's Dealing Classification · 100% confidence The document is a Form 6-K filed by a foreign private issuer, OKYO Pharma LTD, with the SEC. It reports that Panetta Partners Limited, associated with the Executive Chairman, acquired additional shares of the company. The document is short (2691 characters) and primarily serves as an announcement of a shareholding change rather than a detailed report. It includes a news announcement as an exhibit. The content focuses on a director's beneficial share acquisition, which aligns with insider or director share transactions. Therefore, the document fits best under the category of Director's Dealing (DIRS).
2026-03-19 English
6-K - OKYO Pharma Ltd (0001849296) (Filer)
Director's Dealing Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, OKYO Pharma LTD, with the SEC. It announces that a Non-Executive Director, John Brancaccio, acquired 5,000 ordinary shares, increasing his total holdings. The document is short (2614 characters) and primarily serves as an announcement of insider share transactions by a company director. It does not contain financial statements or detailed financial data. According to the filing definitions, reports of personal share transactions by company directors and executives fall under 'Director's Dealing' (DIRS). Therefore, this document is best classified as DIRS with high confidence.
2026-03-19 English
6-K - OKYO Pharma Ltd (0001849296) (Filer)
Director's Dealing Classification · 100% confidence The document is a Form 6-K filed by a foreign private issuer, OKYO Pharma LTD, with the SEC. It announces that Gary Jacob, a company director and Chief Development Officer, has acquired 30,980 ordinary shares, increasing his total holdings. The document is short (2627 characters) and primarily serves as an announcement of a director's personal share transaction. It does not contain financial statements or detailed financial data. Therefore, it fits the category of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives.
2026-03-19 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.